M1 Kliniken Gestion

Gestion contrôle des critères 0/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Attila Strauss

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	2yrs
Propriété du PDG	n/a
Durée moyenne d'occupation des postes de direction	pas de données
Durée moyenne du mandat des membres du conseil d'administration	2.1yrs

Mises à jour récentes de la gestion

Recent updates

PDG

Attila Strauss

2yrs

Titularisation

Mr. Attila Strauss is Member of Management Board & Chief Executive Officer of M1 Kliniken AG since November 24, 2022 and March 2023 respectively. He studied International Trade Management (B.A.) and Inform...

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Sabine Meck	Member of Supervisory Board	9.4yrs	pas de données	pas de données
Uwe Zimdars	Chairman of Supervisory Board	2.1yrs	pas de données	pas de données
Dirk Hempel	Deputy Chairman of Supervisory Board	2.1yrs	pas de données	pas de données

2.1yrs

Durée moyenne de l'emploi

Conseil d'administration expérimenté: Le conseil d'administration de la M12 n'est pas considéré comme expérimenté ( 2.1 années d'ancienneté moyenne), ce qui suggère un nouveau conseil d'administration.

M1 Kliniken Gestion

Gestion contrôle des critères 0/4

Informations clés

Mises à jour récentes de la gestion

M1 Kliniken AG, Annual General Meeting, Jul 17, 2024

M1 Kliniken AG, Annual General Meeting, Jul 13, 2022

M1 Kliniken AG Announces Resignation of Patrick Brenske from the Management Board

Recent updates

New major risk - Revenue size

Investor sentiment improves as stock rises 16%

New major risk - Share price stability

Upcoming dividend of €0.50 per share

Now 21% undervalued

Investor sentiment deteriorates as stock falls 15%

M1 Kliniken AG, Annual General Meeting, Jul 17, 2024

Price target increased by 57% to €27.50

Full year 2023 earnings released: EPS: €0.54 (vs €0.24 in FY 2022)

Investor sentiment improves as stock rises 19%

Investor sentiment improves as stock rises 16%

New minor risk - Financial data availability

Investor sentiment improves as stock rises 15%

New minor risk - Share price stability

Price target increased by 14% to €14.35

Now 21% undervalued

Now 20% undervalued

Price target increased by 10% to €11.85

First half 2023 earnings released: EPS: €0.17 (vs €0.07 in 1H 2022)

Now 20% undervalued

Now 20% undervalued

Now 20% undervalued

New minor risk - Profit margin trend

Full year 2022 earnings: EPS misses analyst expectations

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 16%

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Price target decreased to €10.85

Investor sentiment deteriorated over the past week

M1 Kliniken AG, Annual General Meeting, Jul 13, 2022

Full year 2021 earnings: Revenues miss analyst expectations

Price target decreased to €14.00

M1 Kliniken AG to Report Fiscal Year 2021 Final Results on May 19, 2022

Now 24% undervalued after recent price drop

Now 20% undervalued after recent price drop

Investor sentiment improved over the past week

Price target increased to €20.00

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS €0.37 (vs €0.56 in FY 2019)

New 90-day high: €9.60

Price target lowered to €16.40

M1 Kliniken AG Announces Resignation of Patrick Brenske from the Management Board

Market bids up stock over the past week

New 90-day low: €8.10

M1 Kliniken AG (XTRA:M12) completed the acquisition of 48.16% stake in HAEMATO AG (XTRA:HAE) from MPH Health Care AG (XTRA:93M).

First half earnings released

New 90-day low - €8.92

New 90-day low - €9.04

PDG

Titularisation

Membres du conseil d'administration

Durée moyenne de l'emploi